The data in this study were extracted from previous studies, a list of which is included in the Supporting Information.

Introduction {#sec005}
============

Bladder cancer (BC) is a common cancer of the urinary tract, with an estimated 429,800 new cases of BC and 165,100 deaths annually worldwide \[[@pone.0158891.ref001]\]. Clinically, bladder tumors are classified as non-muscle invasive bladder cancer (NMIBC)(Ta/T1) and muscle-invasive bladder cancer (MIBC)(T2-T4), NMIBC is also called superficial bladder cancer. Although many factors have been identified as risk factors for BC, such as smoking, age, obesity and diabetes, the pathogenesis of BC remains unclear \[[@pone.0158891.ref002], [@pone.0158891.ref003]\]. Cystoscopy and biopsy are the gold standards for the initial diagnosis of BC but are invasive, uncomfortable, and expensive \[[@pone.0158891.ref004], [@pone.0158891.ref005]\]. Therefore, novel biomarkers for early diagnosis, prognostic evaluation and effective treatment of BC are needed.

Ki-67 is a DNA-binding nuclear protein that is expressed throughout the cell cycle in proliferating but not quiescent (G0) cells \[[@pone.0158891.ref006]\]. Ki-67 is a predictive factor for tumor development, and its expression has been correlated with poor prognosis in several types of cancer \[[@pone.0158891.ref007]--[@pone.0158891.ref010]\]. However, the role of Ki-67 in the prognosis of BC remains controversial. Chen et al. \[[@pone.0158891.ref011]\] confirmed that Ki-67 was an independent predictor of tumor recurrence and progression in a study of 72 cases of NMIBC. Makboul and Gontero et al. \[[@pone.0158891.ref012], [@pone.0158891.ref013]\] demonstrated that Ki-67 was only an independent predictor of progression and not recurrence in NMIBC patients. Tanabe et al. \[[@pone.0158891.ref014]\] demonstrated that high Ki-67 expression status might facilitate the selection of chemoradiotherapy-based multimodal approaches in terms of prognosis and quality of life as a result of bladder preservation in MIBC patients. Studies have revealed that Ki-67 is not correlated with or an independent predictor of BC recurrence, progression, and death. For example, Acikalin et al. \[[@pone.0158891.ref015]\] reported that there was no correlation between Ki-67 and tumor recurrence, progression or tumor-related mortality in a study of 68 patients with stage T1 who underwent transurethral resection of the tumor.

The optimal approach to the interpretation and assessment of Ki-67 in clinical practice remains controversial among pathologists. In addition, the roles of Ki-67 expression and clinical significance in BC have not been thoroughly investigated. In this study, we performed a meta-analysis to explore the relationship between Ki-67 expression and its prognostic value in BC. This systematic review and meta-analysis was reported and performed in accordance with PRISMA guidelines ([S3 Table](#pone.0158891.s008){ref-type="supplementary-material"}) \[[@pone.0158891.ref016]\].

Materials and Methods {#sec006}
=====================

Study strategy {#sec007}
--------------

The PubMed, Cochrane, Embase and Web of Knowledge databases were searched systematically for relevant articles published up to February 1, 2016. Because the data in this study were extracted from previous studies, ethical approval from ethics committees was not required.

The search terms were ''bladder," ''urothelial," ''cancer or tumor or neoplasm or carcinoma," ''expression," ''Ki-67 or Ki67 or MIB-1 or MIB 1", and ''prognosis or prognostic or outcome." The criteria for eligibility were as follows: (1) Ki-67 expression evaluated in primary BC tissues; (2) evaluation of the relationship between Ki-67 expression and BC clinicopathological parameters and prognosis; and (3) sufficient information to estimate the hazard ratio (HR) of recurrence-free survival (RFS), progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS) and a 95% confidence intervals (CIs). Papers containing any of the following were excluded: (1) duplicate literature or duplicate data presented at conferences; (2) reviews, no available data, or abstract only; (3) studies of cancer cell lines and animal models; and (4) insufficient data to obtain HR and its standard error. For overlapping articles, only the highest-quality and most-recent literature were retained.

Data extraction and methodological assessment {#sec008}
---------------------------------------------

The following information was recorded for each study: the first author's name, publication year, sample source, number of cases, median or mean of patient age, gender, cancer stage, antibody source and dilution, percentage rate of expression, and follow-up period. We preferred to collect multivariate analysis data. If data were not available, data from univariate analyses of survival outcomes were extracted. All data were extracted by two independent observers (ZMM and ZHC). The quality of the selected articles was assessed according to the Newcastle-Ottawa Scale (NOS) criteria \[[@pone.0158891.ref017]\]. If data could not be obtained from the literature, we regarded the related data as not available.

Statistical analysis {#sec009}
--------------------

The statistical analysis was conducted using Review Manager 5.3 (Cochrane Collaboration, Oxford, UK) and STATA 14.0 (Stata Corporation, TX). HRs and 95% CIs were used to evaluate the relationships between Ki-67 expression and RFS, PFS, OS, and CSS rates. ORs (odds ratios) and 95% CIs were used to estimate the relationships between Ki-67 expression and clinicopathological parameters, including age, sex status, tumor stage, recurrence status, tumor number, and tumor size. The statistical significance of the pooled ORs and HRs was evaluated by the Z test. Heterogeneity among the studies was evaluated with Cochran's Q test and I^2^ tests \[[@pone.0158891.ref018]\]. When the I^2^ statistic results were 0--50%, a fixed-effect model was used to calculate parameters. If the I^2^ statistic results were 50--100%, a random-effects model was considered more appropriate than a fixed-effects model. A p value \< 0.05 was considered statistically significant. Funnel plots and Begg's test were used to evaluate potential publication bias \[[@pone.0158891.ref019]\].

Results {#sec010}
=======

Study characteristics {#sec011}
---------------------

Our search strategy initially identified 412 articles. Following deduplication (n = 60), the two reviewers independently screened the identified titles and abstracts. After manually screening the titles and abstracts, 22 studies were excluded because they were case reports (n = 2), review articles (n = 6), conference abstracts (n = 4), meta-analysis (n = 2) or studies irrelevant to the human studies (n = 8). Seven articles were ultimately excluded due to overlap with previously reported studies (n = 4). Thus, 31 articles published from 2001 to 2016 were included in the final meta-analysis \[[@pone.0158891.ref020]--[@pone.0158891.ref050]\] ([Fig 1](#pone.0158891.g001){ref-type="fig"}).

![Flow chart shows study selection procedure.](pone.0158891.g001){#pone.0158891.g001}

The main characteristics of the 31 studies included in our meta-analysis are presented in [S1 Table](#pone.0158891.s006){ref-type="supplementary-material"}. Of the 31 studies, 5 were conducted in America, five in Germany, five in China, three in Greece, three in Spain, three in Korea, two in Italy, two in Japan, and one each in Portugal, Switzerland, and the UK. In 5 of the 31 studies, patients received intravesical BCG therapy. The follow-up period of the studies ranged from 2 months to 124 months. The age of the patients ranged from 21 to 97 years, and the overall proportion of males was 80.33%.

Positive/high Ki-67 expression was defined by immunohistochemistry (IHC) using different antibodies and cut-off values (range, 5--55%) ([S2 Table](#pone.0158891.s007){ref-type="supplementary-material"}).

Of the 31 studies, 23 provided HRs and 95% CI values directly. Six papers provided the relative risk (RR), and two articles provided OR values, which we used to estimate HR. Of the 31 studies, a significant association between high Ki-67 expression and poor RFS, PFS, OS and CSS was demonstrated in five \[[@pone.0158891.ref022], [@pone.0158891.ref026], [@pone.0158891.ref034], [@pone.0158891.ref035], [@pone.0158891.ref048]\], five \[[@pone.0158891.ref031], [@pone.0158891.ref036], [@pone.0158891.ref043], [@pone.0158891.ref046], [@pone.0158891.ref048]\], six \[[@pone.0158891.ref020], [@pone.0158891.ref024], [@pone.0158891.ref028], [@pone.0158891.ref029], [@pone.0158891.ref031], [@pone.0158891.ref042]\] and seven studies \[[@pone.0158891.ref027], [@pone.0158891.ref030], [@pone.0158891.ref033], [@pone.0158891.ref034], [@pone.0158891.ref042], [@pone.0158891.ref046], [@pone.0158891.ref047]\], respectively. Of the literature, eleven, five, three and two studies linking Ki-67 expression with poor RFS \[[@pone.0158891.ref021], [@pone.0158891.ref025], [@pone.0158891.ref037]--[@pone.0158891.ref041], [@pone.0158891.ref043]--[@pone.0158891.ref045]\], PFS\[[@pone.0158891.ref021], [@pone.0158891.ref025], [@pone.0158891.ref041], [@pone.0158891.ref044], [@pone.0158891.ref049]\], OS \[[@pone.0158891.ref023], [@pone.0158891.ref032], [@pone.0158891.ref041]\] and CSS \[[@pone.0158891.ref043], [@pone.0158891.ref050]\], respectively, lacked statistical significance.

Correlation of high Ki-67 expression with RFS in bladder cancer {#sec012}
---------------------------------------------------------------

Of the 16 studies investigating the association between Ki-67 expression and RFS, 7 involved Asian patients (n = 2163), and 9 involved non-Asian patients (n = 610). The overall HR for BC patients was 1.69 (95% CI 1.33--2.14, P \< 0.0001, n = 2773), with significant heterogeneity (I^2^ = 55%, P = 0.004; [Fig 2](#pone.0158891.g002){ref-type="fig"} and [Table 1](#pone.0158891.t001){ref-type="table"}). Subgroup analyses indicated that the risk was significant in non-Asian patients (HR 2.23, 95% CI 1.82--2.73, P \< 0.00001) with heterogeneity (I^2^ = 33%, P = 0.16), but not in Asian patients (HR 1.36, 95% CI 0.97--1.90, P = 0.07), with significant heterogeneity (I^2^ = 55%, P = 0.04).

![The hazard ratio (HR) of Ki-67 expression associated with RFS in all bladder cancer patients.](pone.0158891.g002){#pone.0158891.g002}

10.1371/journal.pone.0158891.t001

###### Results of subgroup analysis of the association between Ki-67 expression and RFS/PFS/OS/CSS of bladder cancer.

![](pone.0158891.t001){#pone.0158891.t001g}

            Outcome             Studies (n)   Patients   HR     95%CI         P value   Model    Heterogeneity
  --------- ------------------- ------------- ---------- ------ ------------- --------- -------- --------------------
  **RFS**   **All study**       16            2773       1.69   1.33--2.14    0.000     Random   33.49, 55%, 0.004
            **Asian**           7             2163       1.36   0.97--1.90    0.07      Random   13.37, 55%, 0.04
            **Non-Asian**       9             610        2.23   1.82--2.73    0.000     Fixed    11.85, 33%, 0.16
            **Stage T1**        6             927        1.45   1.09--1.93    0.01      Fixed    8.58, 42%, 0.13
            **Stage Ta-T1**     6             774        1.99   1.54--2.57    0.000     Fixed    9.26, 46%, 0.10
            **Stage Ta/1-T4**   4             1072       1.56   0.91--2.66    0.11      Random   12.52, 76%, 0.006
            **UBC**             14            2560       1.79   1.40--2.28    0.000     Random   28.88, 55%, 0.007
            **SCC**             1             152        1.09   0.39--3.08    0.87      Fixed    \-
            **BCG**             5             522        1.63   1.20--2.23    0.002     Fixed    4.42, 10%, 0.35
  **PFS**   **All study**       10            1694       1.89   1.43--2.51    0.000     Fixed    16.34, 45%, 0.06
            **Asian**           4             618        1.35   0.48--3.82    0.57      Random   11.41, 74%, 0.01
            **Non-Asian**       6             1076       2.05   1.45--2.89    0.000     Fixed    4.33, 0%, 0.50
            **Stage T1**        5             799        1.78   1.22--2.60    0.003     Fixed    6.42, 38%, 0.17
            **Stage Ta-T1**     4             799        2.80   1.75--4.49    0.000     Fixed    1.04, 0%, 0.79
            **Stage Ta-T4**     1             96         0.57   0.22--1.49    0.253     Fixed    \-
  **OS**    **All study**       9             1159       2.03   1.31--3.16    0.002     Random   40.37, 80%, 0.000
            **Asian**           2             241        2.97   0.19--47.15   0.44      Random   12.21, 92%, 0.0005
            **Non-Asian**       7             918        1.96   1.26--3.06    0.003     Random   27.12, 78%, 0.0001
            **Stage Ta-T1**     4             638        2.76   1.81--4.20    0.001     Fixed    1.05, 0%, 0.79
            **Stage T2-T4**     1             82         2.33   0.99--5.43    0.05      Fixed    \-
            **Stage Ta/1-T4**   4             439        1.40   0.82--2.40    0.22      Random   15.33, 80%, 0.002
  **CSS**   **All study**       9             2528       1.69   1.47--1.95    0.000     Fixed    10.42, 23%, 0.24
            **Asian**           1             103        1.58   0.56--4.47    0.38      Fixed    \-
            **Non-Asian**       8             2425       1.69   1.47--1.95    0.000     Fixed    10.41, 33%, 0.17
            **Stage T1**        3             695        2.86   1.16--7.02    0.02      Random   4.95, 60%, 0.08
            **Stage Ta-T1**     1             192        3.46   1.22--9.80    0.01      Fixed    \-
            **Stage T2-T4**     1             73         4.70   1.14--19.28   0.032     Fixed    \-
            **Stage Ta/1-T4**   5             1641       1.61   1.39--1.87    0.000     Fixed    0.73, 0%, 0.95

BCG: bacillus Calmette-Guerin; CSS: cancer-specific survival; Fixed: Fixed, Inverse Variance model; HR: hazard ratio; I^2^: I-squared; OS: overall survival; PFS: progression-free survival; Random: Random, I-V heterogeneity model; RFS: recurrence-free survival; SCC: squamous cell carcinoma; UBC: urothelial bladder cancer.

Next, subgroups including tumor stage (six studies for stage T1, six for stages Ta-T1, and four for stages Ta/1-T4) and type of BC (14 studies for urothelial bladder cancer and 1 for squamous cell carcinoma) were analyzed. The analyses indicated that high Ki-67 expression was associated with shorter RFS in stage T1 and stages Ta-T1 patients (HR 1.45, 95% CI 1.09--1.93, P = 0.01; and HR 1.99, 95% CI 1.54--2.57, P \< 0.00001, respectively) with heterogeneity (I^2^ = 42%, P = 0.13; and I^2^ = 46%, P = 0.10, respectively), but no association with shorter RFS was observed in patients in stages Ta/1-T4 (HR 1.56, 95% CI 0.91--2.66, P = 0.11). Moreover, our analyses revealed that Ki-67 expression was associated with shorter RFS in urothelial bladder cancer (HR 1.79, 95% CI 1.40--2.28, P \< 0.00001). No significant association was observed between Ki-67 expression and squamous cell carcinoma (HR 1.09, 95% CI 0.39--3.08, P = 0.87). Furthermore, Ki-67 expression was an independent prognostic factor for BC treated with BCG therapy (HR, 1.63; 95% CI, 1.20--2.23; P = 0.002) ([Table 1](#pone.0158891.t001){ref-type="table"}).

Relationships between Ki-67 expression and RFS in bladder cancer using different cut-off values {#sec013}
-----------------------------------------------------------------------------------------------

Subgroup analysis demonstrated that the relationship between Ki-67 expression and RFS was not significant using different Ki-67 cut-off values (10%, 25%, 50%). The pooled HRs and 95% CIs were as follows: 1.56 (95% CI 1.13--2.16) vs. 1.68 (95% CI 1.27--2.21) for a cut-off value of 10%, 1.61(95% CI 1.16--2.22) vs. 1.97 (95% CI 1.48--2.62) for a cut-off value of 25%, and 1.65 (95% CI 1.27--2.15) vs. 1.99 (95% CI 1.14--3.49) for a cut-off value of 50% ([S1](#pone.0158891.s001){ref-type="supplementary-material"}--[S3](#pone.0158891.s003){ref-type="supplementary-material"} Figs and [S2 Table](#pone.0158891.s007){ref-type="supplementary-material"}).

Correlation between high Ki-67 expression and PFS in bladder cancer {#sec014}
-------------------------------------------------------------------

The pooled HR and 95% CI for RFS provided in ten studies was 1.89, 95% CI 1.43--2.51, P \< 0.0001, with heterogeneity (I^2^ = 45%, P = 0.06; [Fig 3](#pone.0158891.g003){ref-type="fig"} and [Table 1](#pone.0158891.t001){ref-type="table"}). The risk was significant in non-Asian patients but not in Asian patients, and the combined HRs and 95% CIs were as follows: HR 2.05, 95% CI 1.45--2.89, P \< 0.0001; and HR 1.35, 95% CI 0.48--3.82, P = 0.57, respectively. Further subgroup analysis indicated that the risk was higher in the very early stage (stages Ta-T1) compared with stage T1, with the following combined HRs and 95% CIs: HR 2.80, 95% CI 1.75--4.49, P \< 0.00001; HR 1.78, 95% CI 1.22--2.60, P = 0.003, respectively. But no significant association with PFS was observed in patients in stages Ta-T4, and the combined HRs and 95% CIs were as follows: HR 0.57, 95% CI 0.22--1.49, P = 0.253.

![The hazard ratio (HR) of Ki-67 expression associated with PFS in all bladder cancer patients.](pone.0158891.g003){#pone.0158891.g003}

Correlation of high Ki-67 expression with OS and CSS in bladder cancer {#sec015}
----------------------------------------------------------------------

The pooled HR for OS provided in nine studies indicated that Ki-67 expression was associated with worse survival in BC patients (HR = 2.03, 95% CI 1.31--3.16; P = 0.002), with heterogeneity (I^2^ = 80%, P \< 0.0001; [S4 Fig](#pone.0158891.s004){ref-type="supplementary-material"} and [Table 1](#pone.0158891.t001){ref-type="table"}). Subgroup analysis demonstrated that the risk was significant in non-Asian patients but not in Asian patients, and the combined HRs and 95% CIs were as follows: HR 1.96, 95% CI 1.26--3.06, P = 0.003; and HR 2.97, 95% CI 0.19--47.15, P = 0.44, respectively. Next, subgroups including tumor stage (four studies for stages Ta-T1, one for stages T2-T4, and four for stages Ta/1-T4) were analyzed. The analyses indicated that high Ki-67 expression was associated with shorter OS in stages Ta-T1 patients (HR 2.76, 95% CI 1.81--4.20, P = 0.001) with heterogeneity (I^2^ = 0%, P = 0.79), but no association with shorter OS was observed in patients in stages T2-T4 and stages Ta/1-T4 (HR 2.33, 95% CI 0.99--5.43, P = 0.05; and HR 1.40, 95% CI 0.82--2.40, P = 0.22, respectively).

Similarly, the pooled HR for CSS provided in nine studies indicated that Ki-67 expression was associated with worse survival in BC patients (HR = 1.69, 95% CI 1.47--1.95; P \< 0.0001), with heterogeneity (I^2^ = 23%, P = 0.24; [S5 Fig](#pone.0158891.s005){ref-type="supplementary-material"} and [Table 1](#pone.0158891.t001){ref-type="table"}). Subgroup analysis demonstrated the risk was significant in non-Asian patients but not in Asian patients, and the combined HRs and 95% CIs were as follows: HR 1.69, 95% CI 1.47--1.95, P \< 0.0001; and HR 1.58, 95% CI 0.56--4.47, P = 0.38, respectively. Next, subgroups including tumor stage (three studies for stage T1, one for stages Ta-T1, one for stages T2-T4, and five for stages Ta/1-T4) were analyzed. The analyses indicated that high Ki-67 expression was associated with shorter OS in stage T1, stages Ta-T1, stages T2-T4, and stages Ta/1-T4 patients (HR 2.86, 95% CI 1.16--7.02, P = 0.02; HR 3.46, 95% CI 1.22--9.80, P = 0.01; HR 4.70, 95% CI 1.14--19.28, P = 0.032; and HR 1.61, 95% CI 1.39--1.87, P \< 0.00001, respectively).

Relationships between Ki-67 expression and clinicopathological parameters {#sec016}
-------------------------------------------------------------------------

In this meta-analysis, the relationships between clinicopathological characteristics such as age, gender, smoking habits, tumor stage, recurrence status, tumor number, and tumor size and elevated Ki-67 expression were compared on the basis of 31 studies. The results of the meta-analysis revealed significant associations between high Ki-67 expression and higher tumor stage (Ta vs. T1; Ta/1 vs. T2-4), recurrence status, and larger tumor size. The combined ORs and 95% CIs were as follows: OR 0.29, 95% CI 0.19--0.42, P \< 0.00001; OR 0.30, 95% CI 0.09--1.02, P = 0.05; OR 0.43, 95% CI 0.20--0.90, P = 0.02; and OR 1.80, 95% CI 1.26--2.56, P = 0.001, respectively. However, significant associations between Ki-67 and age, gender, smoking habits, and tumor number were not observed in BC patients. The combined ORs and 95% CIs were as follows: OR 1.02, 95% CI 0.41--2.54, P = 0.97; OR 1.09, 95% CI 0.83--1.43, P = 0.55; OR 1.28, 95% CI 0.86--1.89, P = 0.22; and OR 1.28, 95% CI 0.60--2.77, P = 0.52, respectively ([Table 2](#pone.0158891.t002){ref-type="table"}).

10.1371/journal.pone.0158891.t002

###### Results of subgroup analysis of the association between Ki-67 expression and clinicopathological parameters.
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  Outcome of interest                      Studies (n)   Patients   OR     95%CI        P value   Model    Heterogeneity
  ---------------------------------------- ------------- ---------- ------ ------------ --------- -------- -------------------
  **Age (≥65 vs. \<65)**                   2             293        1.02   0.41--2.54   0.97      Random   2.03, 51%, 0.15
  **Gender (Male vs. Female)**             6             1551       1.09   0.83--1.43   0.55      Fixed    3.59, 0%, 0.61
  Asian                                    3             522        0.89   0.56--1.43   0.63      Fixed    1.75, 0%, 0.42
  Non-Asian                                3             1029       1.20   0.86--1.68   0.29      Fixed    0.87, 0%, 0.65
  **Smoke habits (Smoke vs. Non-smoke)**   1             588        1.28   0.86--1.89   0.22      Fixed    \-
  **Ta vs. T1**                            4             570        0.29   0.19--0.42   0.000     Fixed    3.20, 6%, 0.36
  **Ta-1 vs. T2-4**                        3             1010       0.30   0.09--1.02   0.05      Random   12.97, 85%, 0.002
  **Recurrence vs. No recurrence**         6             897        0.43   0.20--0.90   0.02      Random   18.64, 73%, 0.002
  **Multiple vs. Single**                  3             522        1.28   0.60--2.77   0.52      Random   6.28, 68%, 0.04
  **Tumor size (\<3 vs. ≥3cm)**            4             686        1.80   1.26--2.56   0.001     Fixed    3.46, 13%, 0.33

Fixed: Fixed, Inverse Variance model; I^2^: I-squared; OR: odd ratio; Random: Random, I-V heterogeneity model.

Publication bias {#sec017}
----------------

Publication bias was conducted by Begg's test for RFS and PFS of bladder carcinoma, with P values of 0.964 and 0.152, respectively. ([Fig 4A and 4C](#pone.0158891.g004){ref-type="fig"}). Quantitative assessment by Egger's test for RFS and PFS suggested that our analyses were stable (P = 0.350, P = 0.195) ([Fig 4B and 4D](#pone.0158891.g004){ref-type="fig"}).

![Funnel plots were used to evaluate publication bias on RFS and PFS.\
(A) Begg's test was not significant intending no significant bias was observed on RFS. (B) Egger's test was not significant intending no significant bias was observed on RFS. (C) It showed no publication bias on PFS in Begg's test, (D) It showed no publication bias on PFS in Egger's test.](pone.0158891.g004){#pone.0158891.g004}

Discussion {#sec018}
==========

Increasing evidence indicates that BC genomes exhibiting the most complex alterations are associated with a high Ki-67 proliferation index \[[@pone.0158891.ref051]\]. Pichu et al. \[[@pone.0158891.ref052]\] reported that in BC cells, prior exposure to anti-Ki-67 siRNA induces tumor cells to undergo curcumin-induced growth arrest and apoptosis by non-p53 and non-p21-dependent signaling pathways, which may be useful for gene therapy. Wang et al. \[[@pone.0158891.ref053]\] reported that the combined effects of TP53 and Ki-67 revealed predictive value for NMIBC recurrence. However, the relationship between Ki-67 and outcome remains unclear, and the roles and clinical significance of Ki-67 expression in BC have not been thoroughly investigated \[[@pone.0158891.ref054]\].

In the present study, the analyses of the pooled data indicated that (1) BC patients with high Ki-67 expression had a lower survival rate; (2) high Ki-67 expression was associated with the more aggressive clinical stage and larger tumor size in BC patients; (3) aberrant Ki-67 expression was higher in recurrent BC than in non-recurrent BC; (4) Ki-67 expression was not strongly associated with age, gender, and tumor number in BC patients; (5) a strong relationship between poor prognostic indicators and Ki-67 expression was established only for European-American patients. The correlation between Ki-67 expression and survival outcome (RFS/PFS/OS/CSS) did not reach statistical significance in Asian patients. Our study provides insights on the results of individual studies focused on the hypothesis that Ki-67 is a prognostic factor for BC and suggests that adjuvant therapy may be helpful in the high-risk subgroup of patients. Although further validation and investigation are needed, these data provide new insights on the biological aggressiveness of BC in Asian versus in non-Asian patients.

The biological mechanism of Ki-67 explains its prognostic significance in BC. Ki-67 is an index of cell proliferation and a measure of cell growth fraction during the G1, S, G2 and M stages of the cell cycle and is widely applied in immunohistochemistry (IHC) to estimate the activities of cell proliferation in many cancers. Some researches investigated the relationships between the Ki-67 and distant metastases \[[@pone.0158891.ref055], [@pone.0158891.ref056]\]. They found that Ki-67 expression was upregulated in the transforming growth factor-β1 (TGF-β1) treated tumors, and TGF-β1 promotes EMT (epithelial-to-mesenchymal transition), migration, and invasion in bladder cancer cells \[[@pone.0158891.ref057]\]. Furthermore, it was showed that highly Ki-67 may induce EMT by increasing the expression of vimentin, which enhances cancer cell invasion and metastatic \[[@pone.0158891.ref058]\].

The present meta-analysis is the first study to systematically evaluate the associations between Ki-67 expression and clinicopathological features and prognostic factors in BC. Ki-67 can be considered an oncogene, and its activation may contribute to tumor progression and poor prognosis. Based on this meta-analysis, we suggest that Ki-67 expression in BC tends to indicate a poor prognosis.

Several limitations of this study must be acknowledged. In the included studies, the antibodies used to detect Ki-67 expression were not identical (anti-Ki67 mAb and anti-MIB-1 mAb). The definitions of the cut-off value also differed. Clinical factors such as race, age, and the use of different chemotherapies in each study may also be sources of bias. Non-English studies, unpublished studies, and studies that did not provide sufficient data to calculate HRs were not included in the assessment of the predictive value of Ki-67 for survival. These approaches may have produced errors due to the inclusion of inaccurate readings. Finally, although we included 31 studies comprising 5147 cases in this meta-analysis, few studies were categorized for subgroup analysis, and several survival subgroup analyses data lack. Therefore, more well-designed and large-scale trials are needed to confirm these findings.

In conclusion, our meta-analysis confirmed the significant associations between Ki-67 expression and clinicopathological features and prognostic factors in BC. Although subgroup analysis indicated no significant association between Ki-67 expression and BC prognosis in Asian patients. Our meta-analysis demonstrates that Ki-67 has a detrimental effect on clinicopathological features and recurrence status in BC. Therefore, Ki-67 could serve as an independent prognostic factor of RFS, PFS, OS and CSS in European-American patients. Ki-67 may be a novel candidate for BC genotyping and an indicator for predicting the prognosis of BC patients.

Supporting Information {#sec019}
======================

###### Cutoff value ≥ 10% and cutoff value \< 10%.

**HR of Ki-67 expression associated with RFS in all BC patients subgroup.** Abbreviations: HR, hazard ratio; RFS, recurrence-free survival; BC, bladder cancer.

(TIF)

###### 

Click here for additional data file.

###### Cutoff value ≥ 25% and cutoff value \< 25%

**. HR of Ki-67 expression associated with RFS in all BC patients subgroup.** Abbreviations: HR, hazard ratio; RFS, recurrence-free survival; BC, bladder cancer.

(TIF)

###### 

Click here for additional data file.

###### Cutoff value ≥ 50% and cutoff value \< 50%

**. HR of Ki-67 expression associated with RFS in all BC patients subgroup**. Abbreviations: HR, hazard ratio; RFS, recurrence-free survival; BC, bladder cancer.

(TIF)

###### 

Click here for additional data file.

###### HR of Ki-67 expression associated with OS in all BC patients.

Abbreviations: HR, hazard ratio; OS, overall survival; BC, bladder cancer.

(TIF)

###### 

Click here for additional data file.

###### HR of Ki-67 expression associated with CSS in all BC patients.
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